Concise review: Mesenchymal stem cells for diabetes

Juan Dominguez-Bendala, Giacomo Lanzoni, Luca A Inverardi, Camillo Ricordi

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSCs) have already made their mark in the young field of regenerative medicine. Easily derived from many adult tissues, their therapeutic worth has already been validated for a number of conditions. Unlike embryonic stem cells, neither their procurement nor their use is deemed controversial. Here we review the potential use of MSCs for the treatment of type 1 diabetes mellitus, a devastating chronic disease in which the insulin-producing cells of the pancreas (the β-cells) are the target of an autoimmune process. It has been hypothesized that stem cell derived β-cells may be used to replenish the islet mass in diabetic patients, making islet transplantation (a form of cell therapy that has already proven effective at clinically restoring normoglycemia) available to millions of prospective patients. Here we review the most current advances in the design and application of protocols for the differentiation of transplantable β-cells, with a special emphasis in analyzing MSC potency according to their tissue of origin. Although no single method appears to be ripe enough for clinical trials yet, recent progress in reprogramming (a biotechnological breakthrough that relativizes the thus far insurmountable barriers between embryonal germ layers) bodes well for the rise of MSCs as a potential weapon of choice to develop personalized therapies for type 1 diabetes.

Original languageEnglish
Pages (from-to)59-63
Number of pages5
JournalStem cells translational medicine
Volume1
Issue number1
DOIs
StatePublished - Dec 1 2012

Fingerprint

Mesenchymal Stromal Cells
Type 1 Diabetes Mellitus
Germ Layers
Islets of Langerhans Transplantation
Regenerative Medicine
Weapons
Embryonic Stem Cells
Cell- and Tissue-Based Therapy
Cell Differentiation
Pancreas
Chronic Disease
Stem Cells
Therapeutics
Clinical Trials
Insulin

Keywords

  • Adult stem cells
  • Diabetes
  • Mesenchymal stem cells
  • Plasticity
  • Stem cell transplantation
  • Stem cells

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Medicine(all)

Cite this

Concise review : Mesenchymal stem cells for diabetes. / Dominguez-Bendala, Juan; Lanzoni, Giacomo; Inverardi, Luca A; Ricordi, Camillo.

In: Stem cells translational medicine, Vol. 1, No. 1, 01.12.2012, p. 59-63.

Research output: Contribution to journalArticle

@article{eb9210e89acd4bf0badff92fdd8ccb18,
title = "Concise review: Mesenchymal stem cells for diabetes",
abstract = "Mesenchymal stem cells (MSCs) have already made their mark in the young field of regenerative medicine. Easily derived from many adult tissues, their therapeutic worth has already been validated for a number of conditions. Unlike embryonic stem cells, neither their procurement nor their use is deemed controversial. Here we review the potential use of MSCs for the treatment of type 1 diabetes mellitus, a devastating chronic disease in which the insulin-producing cells of the pancreas (the β-cells) are the target of an autoimmune process. It has been hypothesized that stem cell derived β-cells may be used to replenish the islet mass in diabetic patients, making islet transplantation (a form of cell therapy that has already proven effective at clinically restoring normoglycemia) available to millions of prospective patients. Here we review the most current advances in the design and application of protocols for the differentiation of transplantable β-cells, with a special emphasis in analyzing MSC potency according to their tissue of origin. Although no single method appears to be ripe enough for clinical trials yet, recent progress in reprogramming (a biotechnological breakthrough that relativizes the thus far insurmountable barriers between embryonal germ layers) bodes well for the rise of MSCs as a potential weapon of choice to develop personalized therapies for type 1 diabetes.",
keywords = "Adult stem cells, Diabetes, Mesenchymal stem cells, Plasticity, Stem cell transplantation, Stem cells",
author = "Juan Dominguez-Bendala and Giacomo Lanzoni and Inverardi, {Luca A} and Camillo Ricordi",
year = "2012",
month = "12",
day = "1",
doi = "10.5966/sctm.2011-0017",
language = "English",
volume = "1",
pages = "59--63",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - Concise review

T2 - Mesenchymal stem cells for diabetes

AU - Dominguez-Bendala, Juan

AU - Lanzoni, Giacomo

AU - Inverardi, Luca A

AU - Ricordi, Camillo

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Mesenchymal stem cells (MSCs) have already made their mark in the young field of regenerative medicine. Easily derived from many adult tissues, their therapeutic worth has already been validated for a number of conditions. Unlike embryonic stem cells, neither their procurement nor their use is deemed controversial. Here we review the potential use of MSCs for the treatment of type 1 diabetes mellitus, a devastating chronic disease in which the insulin-producing cells of the pancreas (the β-cells) are the target of an autoimmune process. It has been hypothesized that stem cell derived β-cells may be used to replenish the islet mass in diabetic patients, making islet transplantation (a form of cell therapy that has already proven effective at clinically restoring normoglycemia) available to millions of prospective patients. Here we review the most current advances in the design and application of protocols for the differentiation of transplantable β-cells, with a special emphasis in analyzing MSC potency according to their tissue of origin. Although no single method appears to be ripe enough for clinical trials yet, recent progress in reprogramming (a biotechnological breakthrough that relativizes the thus far insurmountable barriers between embryonal germ layers) bodes well for the rise of MSCs as a potential weapon of choice to develop personalized therapies for type 1 diabetes.

AB - Mesenchymal stem cells (MSCs) have already made their mark in the young field of regenerative medicine. Easily derived from many adult tissues, their therapeutic worth has already been validated for a number of conditions. Unlike embryonic stem cells, neither their procurement nor their use is deemed controversial. Here we review the potential use of MSCs for the treatment of type 1 diabetes mellitus, a devastating chronic disease in which the insulin-producing cells of the pancreas (the β-cells) are the target of an autoimmune process. It has been hypothesized that stem cell derived β-cells may be used to replenish the islet mass in diabetic patients, making islet transplantation (a form of cell therapy that has already proven effective at clinically restoring normoglycemia) available to millions of prospective patients. Here we review the most current advances in the design and application of protocols for the differentiation of transplantable β-cells, with a special emphasis in analyzing MSC potency according to their tissue of origin. Although no single method appears to be ripe enough for clinical trials yet, recent progress in reprogramming (a biotechnological breakthrough that relativizes the thus far insurmountable barriers between embryonal germ layers) bodes well for the rise of MSCs as a potential weapon of choice to develop personalized therapies for type 1 diabetes.

KW - Adult stem cells

KW - Diabetes

KW - Mesenchymal stem cells

KW - Plasticity

KW - Stem cell transplantation

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84872018640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872018640&partnerID=8YFLogxK

U2 - 10.5966/sctm.2011-0017

DO - 10.5966/sctm.2011-0017

M3 - Article

C2 - 23197641

AN - SCOPUS:84872018640

VL - 1

SP - 59

EP - 63

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 1

ER -